Grants and Contributions:
Title:
Development of first in vitro diagnostic kit for Endometriosis
Agreement Number:
893052
Agreement Value:
$0.00
Agreement Date:
Oct 2, 2017 - Jun 30, 2018
Description:
SYNG Pharma is developing first, in vitro test for endometriosis. This project will validate analytical methods for antigen antibody detection using different matrices, development of lateral flow device and generate new IP for detection of a new biomarker for endometriosis.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Kingston, Ontario, CA K7P 2A4
Reference Number:
172-2018-2019-Q1-893052
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
842703845
Recipient Type:
For-profit organization
Additional Information:
The end date of this agreement has been modified by 91 days.
Amendment Date
Apr 3, 2018
Recipient's Legal Name:
Syng Pharmaceuticals Inc.
Federal Riding Name:
Kingston and the Islands
Federal Riding Number:
35044
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
54171
Amendments: